Lawrence H Boise

List of Publications by Year in Descending Order

236 papers	22,779 citations	53 h-index	150 g-index
250 ext. papers	24,986 ext. citations	5.9 avg, IF	6.15 L-index

#	Paper	IF	Citations
236	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. *Blood*, **2021**, 138, 1612-1612	2.2	
235	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. *Blood*, **2021**, 138, 1624-1624	2.2	
234	Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma. *Blood*, **2021**, 138, 1589-1589	2.2	
233	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. *Blood*, **2021**, 138, 1611-1611	2.2	
232	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*, **2021**, 137, 3604-3615	2.2	11
231	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. *Nature Communications*, **2021**, 12, 1714	17.4	19
230	BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. *Blood and Lymphatic Cancer: Targets and Therapy*, **2021**, 11, 11-24	2.6	2
229	Oncolytic herpes simplex virus infects myeloma cells and. *Molecular Therapy - Oncolytics*, **2021**, 20, 519-531	5.1	3
228	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. *American Journal of Hematology*, **2021**, 96, E68-E71	7.1	3
227	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. *American Journal of Hematology*, **2021**, 96, 418-427	7.1	25
226	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. *Cell Reports*, **2021**, 34, 108532	10.6	15
225	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 3178-3189	12.9	1
224	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	3
223	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. *Blood Cancer Discovery*, **2021**, 2, 600-615	7	2
222	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. *Nature Communications*, **2020**, 11, 1228	17.4	24
221	CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. *Cell Reports*, **2020**, 31, 107815	10.6	10
220	TGF-□ causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. *Theranostics*, **2020**, 10, 7656-7670	12.1	13

219	Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 125	7	3
218	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. *Blood Cancer Journal*, **2020**, 10, 40	7	7
217	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1928-1937	2.2	56
216	Game of Bones: How Myeloma Manipulates Its Microenvironment. *Frontiers in Oncology*, **2020**, 10, 625199	3.3	5
215	The prodomain of caspase-3 regulates its own removal and caspase activation. *Cell Death Discovery*, **2019**, 5, 56	6.9	32
214	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. *Leukemia*, **2019**, 33, 1291-1296	10.7	20
213	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. *Frontiers in Immunology*, **2019**, 10, 1121	8.4	49
212	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. *Cancer*, **2019**, 125, 2991-3000	6.4	47
211	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. *Nature Communications*, **2019**, 10, 1911	17.4	53
210	Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma. *Cancer Research*, **2019**, 79, 2102-2103	10.1	8
209	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 332-344	2	13
208	Cancer Metabolism and the Evasion of Apoptotic Cell Death. *Cancers*, **2019**, 11,	6.6	50
207	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. *JCI Insight*, **2019**, 5,	9.9	55
206	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. *Blood*, **2019**, 134, 926-926	2.2	10
205	Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients. *Blood*, **2019**, 134, 572-572	2.2	4
204	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. *Blood*, **2019**, 134, 4407-4407	2.2	2
203	The Role of Proteasome Activator PA28 In Multiple Myeloma. *Blood*, **2019**, 134, 5499-5499	2.2	
202	Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease. *Blood*, **2019**, 134, 858-858	2.2	1

201	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. *Blood*, **2019**, 134, 318-318	2.2	
200	Myeloma's sound of silencing. *Blood*, **2019**, 134, 1116-1117	2.2	
199	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. *Blood Advances*, **2019**, 3, 3214-3227	7.8	9
198	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. *Blood Cancer Journal*, **2019**, 9, 94	7	59
197	Safety and survival outcomes for bloodless transplantation in patients with myeloma. *Cancer*, **2019**, 125, 185-193	6.4	3
196	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer*, **2019**, 125, 416-423	6.4	22
195	14-3-3□binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. *Leukemia*, **2018**, 32, 744-751	10.7	8
194	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. *Cancer Cell*, **2018**, 34, 315-330.e7	24.3	43
193	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. *Blood*, **2018**, 132, 3241-3241	2.2	1
192	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. *Blood*, **2018**, 132, 952-952	2.2	3
191	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. *Blood*, **2018**, 132, 1884-1884	2.2	1
190	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3282-3282	2.2	2
189	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*, **2018**, 132, 3294-3294	2.2	2
188	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 5647-5647	2.2	2
187	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3302-3302	2.2	
186	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. *Blood*, **2018**, 132, 405-405	2.2	
185	Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival. *Blood*, **2018**, 132, 3174-3174	2.2	
184	A Role for Syntenin-1 in Multiple Myeloma Cell Survival. *Blood*, **2018**, 132, 1008-1008	2.2	

183	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. *Blood*, **2018**, 132, 951-951	2.2	0
182	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. *Journal of Oncology Practice*, **2018**, 14, 561-564	3.1	3
181	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. *Nature Communications*, **2018**, 9, 5341	17.4	227
180	A miRaculous new therapy in myeloma?. *Blood*, **2018**, 132, 983-985	2.2	1
179	Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. *FEBS Journal*, **2018**, 285, 2626-2640	5.7	7
178	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. *Cell Metabolism*, **2017**, 25, 358-373	24.6	83
177	Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. *Blood*, **2017**, 129, 1969-1979	2.2	57
176	HMG-CoA synthase 1 is a synthetic lethal partner of BRAF in human cancers. *Journal of Biological Chemistry*, **2017**, 292, 10142-10152	5.4	18
175	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. *Nucleic Acids Research*, **2017**, 45, 2396-2407	20.1	48
174	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. *Oncogene*, **2017**, 36, 4224-4232	9.2	11
173	Potential application of SERS for arsenic speciation in biological matrices. *Analytical and Bioanalytical Chemistry*, **2017**, 409, 4683-4695	4.4	4
172	Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. *FEBS Letters*, **2017**, 591, 240-251	3.8	44
171	TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. *Blood Advances*, **2017**, 1, 1848-1853	7.8	1
170	CD86 regulates myeloma cell survival. *Blood Advances*, **2017**, 1, 2307-2319	7.8	9
169	Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. *Oncogene*, **2016**, 35, 479-90	9.2	9
168	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. *Cancer Biology and Therapy*, **2016**, 17, 769-77	4.6	11
167	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
166	Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. *Oncogene*, **2016**, 35, 3955-64	9.2	47

165	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. *Nucleic Acids Research*, **2016**, 44, e69	20.1	9
164	Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1009-1010, 55-65	3.2	26
163	Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. *Leukemia*, **2016**, 30, 1086-93	10.7	85
162	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. *Blood*, **2016**, 128, 2108-2108	2.2	2
161	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. *Oncotarget*, **2016**, 7, 59727-59741	3.3	18
160	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. *Oncotarget*, **2016**, 7, 27753-63	3.3	15
159	Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. *Blood*, **2016**, 128, 4524-4524	2.2	
158	CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. *Journal of Immunology*, **2015**, 194, 4717-28	5.3	44
157	Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. *British Journal of Haematology*, **2015**, 169, 423-34	4.5	72
156	Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-B pathway. *International Journal of Cancer*, **2015**, 136, 2341-51	7.5	12
155	How I treat high-risk myeloma. *Blood*, **2015**, 126, 1536-43	2.2	66
154	DUB-ling down on B-cell malignancies. *Blood*, **2015**, 125, 3522-3	2.2	3
153	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. *Molecular Cancer Research*, **2015**, 13, 1163-73	6.6	34
152	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). *Blood*, **2015**, 126, 5344-5344	2.2	1
151	Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). *Blood*, **2015**, 126, 4202-4202	2.2	
150	Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy. *Blood*, **2015**, 126, 2049-2049	2.2	
149	Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. *Leukemia*, **2014**, 28, 690-3	10.7	135
148	Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin. *Chemical Research in Toxicology*, **2014**, 27, 754-64	4	19

147	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. *Blood*, **2014**, 123, 3269-76	2.2	59
146	The Tao of myeloma. *Blood*, **2014**, 124, 1873-9	2.2	42
145	CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. *Blood*, **2014**, 123, 3770-9	2.2	60
144	To Gli or not to Gli. *Blood*, **2014**, 124, 2008-9	2.2	1
143	Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. *Cancer Informatics*, **2014**, 13, 49-53	2.4	16
142	Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation. *Journal of Biological Chemistry*, **2014**, 289, 23629-40	5.4	33
141	Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independently of catalytic function. *Journal of Cell Science*, **2014**, 127, 2217-26	5.3	21
140	Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts. *Journal of Lipid Research*, **2014**, 55, 1298-309	6.3	47
139	Mir-155 Expression Raises the Apoptotic Threshold in Waldenstrm Macroglobulinemia By Inhibition of FOXO3a and Bim. *Blood*, **2014**, 124, 1671-1671	2.2	1
138	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. *Blood*, **2014**, 124, 2139-2139	2.2	11
137	Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. *Blood*, **2014**, 124, 5773-5773	2.2	1
136	Detection of NFKB2 3end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma. *Blood*, **2014**, 124, 2138-2138	2.2	
135	Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. *Blood*, **2014**, 124, 3447-3447	2.2	
134	Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. *Blood*, **2014**, 124, 2604-2604	2.2	
133	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. *Blood*, **2014**, 124, 4726-4726	2.2	
132	Induction of Bim-Dependent and -Independent Apoptosis in Multiple Myeloma. *Blood*, **2014**, 124, 4716-4716	2.2	
131	Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMC Cell Biology*, **2013**, 14, 32		564
130	Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. *Cancer*, **2013**, 119, 4119-28	6.4	33

129	The future of drug development and therapy in myeloma. *Seminars in Oncology*, **2013**, 40, 652-8	5.5	6
128	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. *Blood and Lymphatic Cancer: Targets and Therapy*, **2013**, 41	2.6	
127	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. *Blood*, **2013**, 122, 1924-1924	2.2	2
126	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. *Blood*, **2013**, 122, 3135-3135	2.2	6
125	Efficacy Of ABT-199 In Multiple Myeloma. *Blood*, **2013**, 122, 4453-4453	2.2	2
124	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. *Journal of Clinical Oncology*, **2013**, 31, 8540-8540	2.2	1
123	CD28 and CD86 Regulate Integrin Surface Expression In Multiple Myeloma. *Blood*, **2013**, 122, 4450-4450	2.2	
122	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). *Blood*, **2013**, 122, 5606-5606	2.2	
121	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. *Blood*, **2013**, 122, 5582-5582	2.2	
120	Combined Carfilzomib and Selective PI3K□Inhibition (TGR1202) Results In Enhanced Myeloma Cell Apoptosis. *Blood*, **2013**, 122, 3224-3224	2.2	
119	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. *Blood*, **2013**, 122, 1929-1929	2.2	
118	Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma. *Blood*, **2013**, 122, 4446-4446	2.2	1
117	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). *Blood*, **2013**, 122, 3148-3148	2.2	
116	Heterogeneous Bcl-2 Family Expression In Waldenstr□m Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis. *Blood*, **2013**, 122, 4287-4287	2.2	
115	Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. *Blood*, **2013**, 122, 3171-3171	2.2	
114	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. *Blood*, **2013**, 122, 1856-1856	2.2	
113	The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. *Leukemia Research*, **2012**, 36, 784-90	2.7	7
112	KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. *Blood*, **2012**, 119, 1450-8	2.2	47

111	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	13.2	2783
110	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. *Blood*, **2012**, 120, 2072-2072	2.2	2
109	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. *Blood*, **2012**, 120, 4289-4289	2.2	1
108	Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. *PLoS ONE*, **2012**, 7, e52662	3.7	10
107	Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.. *Blood*, **2012**, 120, 2953-2953	2.2	
106	Bcl-xL Protects From UPR-Associated Apoptosis During Plasma Cell Differentiation. *Blood*, **2012**, 120, 3288-3288	2.2	2
105	CD28 and CD86 Are Necessary for Myeloma Cell Survival.. *Blood*, **2012**, 120, 2946-2946	2.2	
104	Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma. *Blood*, **2012**, 120, 3974-3974	2.2	
103	Targeting the Cellular and Molecular Components of CD28 Mediated Survival Signaling in Multiple Myeloma. *Blood*, **2012**, 120, 722-722	2.2	
102	Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. *Blood*, **2012**, 120, 4024-4024	2.2	
101	TGR-1202: A Novel, Targeted PI3K□Inhibitor in Multiple Myeloma. *Blood*, **2012**, 120, 5018-5018	2.2	
100	The Role of 14-3-3□In Regulation of Proteasome Inhibitor Bortezomib Sensitivity in Multiple Myeloma. *Blood*, **2012**, 120, 1845-1845	2.2	
99	Integrin □7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. *Blood*, **2011**, 117, 6202-13	2.2	104
98	Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. *Blood*, **2011**, 118, 6368-79	2.2	95
97	Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. *Blood*, **2011**, 118, 1329-39	2.2	92
96	A MCP1 fusokine with CCR2-specific tumoricidal activity. *Molecular Cancer*, **2011**, 10, 121	42.1	16
95	Extraction tool and matrix effects on arsenic speciation analysis in cell lines. *Analytica Chimica Acta*, **2011**, 699, 187-92	6.6	10
94	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. *Autophagy*, **2011**, 7, 448-9	10.2	4

93	CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. *Journal of Immunology*, **2011**, 187, 1243-53	5.3	72
92	Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. *Journal of Experimental Medicine*, **2011**, 208, 1435-46	16.6	131
91	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. *Blood*, **2011**, 118, 1855-1855	2.2	4
90	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. *Blood*, **2011**, 118, 3994-3994	2.2	2
89	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,. *Blood*, **2011**, 118, 3954-3954	2.2	
88	Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells. *Blood*, **2011**, 118, 182-182	2.2	
87	Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment. *Blood*, **2011**, 118, 473-473	2.2	
86	Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. *Blood*, **2011**, 118, 2891-2891	2.2	
85	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. *Blood*, **2011**, 118, 3950-3950	2.2	0
84	ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma. *Blood*, **2011**, 118, 2884-2884	2.2	
83	Validation of the Function of 14-3-3 in Multiple Myeloma (MM). *Blood*, **2011**, 118, 1369-1369	2.2	
82	MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells. *Blood*, **2011**, 118, 1870-1870	2.2	
81	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. *Oncology*, **2011**, 25 Suppl 2, 25-31	1.8	4
80	Aiming at WM with both barrels blocked. *Blood*, **2010**, 115, 4007-8	2.2	2
79	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. *Blood*, **2010**, 116, 5285-8	2.2	20
78	High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. *Cancer Chemotherapy and Pharmacology*, **2010**, 66, 129-40	3.5	16
77	Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma. *Blood*, **2010**, 116, 132-132	2.2	1
76	Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-xL/BCL-2 In Multiple Myeloma. *Blood*, **2010**, 116, 4054-4054	2.2	

75	Long Term Humoral Immunity Is Dependent on CD28 Expression In Plasma Cells. *Blood*, **2010**, 116, 1737-1737	2.2	
74	Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. *Journal of Biological Chemistry*, **2009**, 284, 12886-95	5.4	33
73	Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. *Molecular Cancer Therapeutics*, **2009**, 8, 1197-206	6.1	46
72	Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. *Leukemia*, **2009**, 23, 2181-3	10.7	41
71	Speciation, formation, stability and analytical challenges of human arsenic metabolites. *Journal of Analytical Atomic Spectrometry*, **2009**, 24, 1397-1405	3.7	34
70	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. *Blood*, **2009**, 114, 1689-1689	2.2	1
69	Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines.. *Blood*, **2009**, 114, 2851-2851	2.2	
68	BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. *Blood*, **2008**, 111, 5152-62	2.2	68
67	Bak Binding to Bcl-xL and Not to Mcl-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines. *Blood*, **2008**, 112, 3675-3675	2.2	
66	Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release. *Molecular and Cellular Biology*, **2007**, 27, 1771-83	4.8	44
65	CD28-mediated regulation of multiple myeloma cell proliferation and survival. *Blood*, **2007**, 109, 5002-10	2.2	98
64	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. *Blood*, **2006**, 107, 4907-16	2.2	825
63	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. *Blood*, **2006**, 108, 1966-1966	2.2	2
62	S-Dimethylarsinoglutathione (SGLU/ZIO101) Is a Novel Active Organic Arsenical That Displays a Unique Gene Expression Profile in Myeloma Cells.. *Blood*, **2006**, 108, 5043-5043	2.2	
61	Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. *Oncogene*, **2005**, 24, 6354-66	9.2	35
60	Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis. *Journal of Biological Chemistry*, **2005**, 280, 29578-87	5.4	131
59	Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. *Cancer Research*, **2005**, 65, 11510-9	10.1	271
58	N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. *Leukemia and Lymphoma*, **2005**, 46, 899-908	1.9	17

57	Regulation of RelB expression during the initiation of dendritic cell differentiation. *Molecular and Cellular Biology*, **2005**, 25, 7900-16	4.8	37
56	Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. *Journal of Biological Chemistry*, **2005**, 280, 28412-23	5.4	37
55	In Vitro Activity of a Novel Organic Arsenical (S-Dimethylarsino-Glutathione, ZIO-101) Against Multiple Myeloma.. *Blood*, **2005**, 106, 5163-5163	2.2	1
54	CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.. *Blood*, **2005**, 106, 355-355	2.2	
53	Glutathione and Glutathione Utilizing Enzymes Are Key Determinants in the Sensitivity of Myeloma Cells to Arsenic Trioxide as Well as Its Mechanism of Action.. *Blood*, **2005**, 106, 5143-5143	2.2	
52	Gene Profile during Arsenic Trioxide-Induced Apoptosis in Multiple Myeloma: Strong Anti-Oxidantive Response and Pro-Apoptotic Imbalance.. *Blood*, **2005**, 106, 5175-5175	2.2	
51	Upstream regulatory role for XIAP in receptor-mediated apoptosis. *Molecular and Cellular Biology*, **2004**, 24, 7003-14	4.8	92
50	R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. *Molecular Cancer Therapeutics*, **2004**, 3, 179-86	6.1	29
49	Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. *Leukemia and Lymphoma*, **2003**, 44, 2123-34	1.9	15
48	Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. *Blood*, **2003**, 101, 2321-7	2.2	79
47	Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. *Molecular Cancer Therapeutics*, **2003**, 2, 1155-64	6.1	43
46	Arsenic trioxide in multiple myeloma: rationale and future directions. *Cancer Journal (Sudbury, Mass)*, **2002**, 8, 12-25	2.2	30
45	Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. *Clinical Cancer Research*, **2002**, 8, 3658-68	12.9	126
44	Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. *Blood*, **2001**, 98, 805-13	2.2	231
43	Cloning and analysis of Bcl-2 family genes. *Methods in Cell Biology*, **2001**, 66, 29-47	1.8	3
42	Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. *Oncogene*, **2001**, 20, 7029-40	9.2	55
41	Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. *Journal of Biological Chemistry*, **2001**, 276, 6320-6	5.4	115
40	Mitochondria as targets for established and novel anti-cancer agents. *Drug Resistance Updates*, **2001**, 4, 85-91	23.2	47

39	Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?. *Trends in Microbiology*, **2001**, 9, 64-7	12.4	93
38	Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells. *Scientific World Journal, The*, **2001**, 1, 110	2.2	
37	Conversion from a Type I to a Type II Death Receptor-Mediated Pathway through A Partial Inhibition of Caspase-8. *Scientific World Journal, The*, **2001**, 1, 98	2.2	
36	Regulation of Bcl-xL: a little bit of this and a little bit of STAT. *Current Opinion in Oncology*, **2000**, 12, 543-9	4.2	188
35	Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). *Biochemical Pharmacology*, **2000**, 60, 1445-56	6	37
34	Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. *Journal of Biological Chemistry*, **2000**, 275, 31546-53	5.4	46
33	CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. *Journal of Immunology*, **2000**, 165, 5105-11	5.3	82
32	Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-alpha-induced cell death in a Bcl-2 cleavage-independent fashion. *Journal of Biological Chemistry*, **1999**, 274, 18552-8	5.4	35
31	Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. *Leukemia*, **1999**, 13, 1564-73	10.7	44
30	Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. *Biochemical and Biophysical Research Communications*, **1999**, 259, 67-72	3.4	58
29	Interleukin 2-mediated uncoupling of T cell receptor alpha/beta from CD3 signaling. *Journal of Experimental Medicine*, **1998**, 188, 1575-86	16.6	16
28	Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. *International Immunology*, **1997**, 9, 945-53	4.9	35
27	Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 3759-64	11.5	201
26	Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis. *Cell Death and Differentiation*, **1997**, 4, 294-303	12.7	6
25	Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. *Journal of Clinical Immunology*, **1997**, 17, 234-46	5.7	13
24	Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line. *Journal of Neurochemistry*, **1996**, 67, 1908-20	6	50
23	Hierarchical control of lymphocyte survival. *Science*, **1996**, 274, 67-8	33.3	180
22	Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays. *Journal of Immunological Methods*, **1996**, 191, 143-8	2.5	8

21	Bax-independent inhibition of apoptosis by Bcl-XL. *Nature*, **1996**, 379, 554-6	50.4	454
20	Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. *Genes and Development*, **1996**, 10, 2621-31	12.6	196
19	Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). *Journal of Biological Chemistry*, **1996**, 271, 6306-12	5.4	155
18	Regulation of T cell activation by CD28 and CTLA4. *Advances in Experimental Medicine and Biology*, **1996**, 406, 209-17	3.6	60
17	CD28 and apoptosis. *Current Opinion in Immunology*, **1995**, 7, 620-5	7.8	123
16	Bcl-XL and Bcl-2 repress a common pathway of cell death. *Journal of Experimental Medicine*, **1995**, 182, 821-8	16.6	360
15	CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. *Immunity*, **1995**, 3, 87-98	32.3	1003
14	Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. *Cell*, **1995**, 80, 285-91	56.2	1840
13	Receptors that regulate T-cell susceptibility to apoptotic cell death. *Annals of the New York Academy of Sciences*, **1995**, 766, 70-80	6.5	19
12	Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 7834-8	11.5	729
11	Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 5491-5	11.5	133
10	bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 4304-8	11.5	245
9	The role of bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. *European Journal of Immunology*, **1995**, 25, 1352-7	6.1	136
8	Bcl-2 and Bcl-2-related proteins in apoptosis regulation. *Current Topics in Microbiology and Immunology*, **1995**, 200, 107-21	3.3	141
7	Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 7350-4	11.5	215
6	Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 9238-42	11.5	521
5	bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. *Cell*, **1993**, 74, 597-608	56.2	2712
4	Components of intrinsic drug resistance in the rat hepatoma. *Biochemical Pharmacology*, **1992**, 43, 331-42	4.2	8

3	In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells. *Biochemical Pharmacology*, **1991**, 42, 853-67[6]	14
2	Multiple myeloma immunoglobulin translocations portend poor prognosis	1
1	Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma	1